Temporal Patterns of Glucagon and Its Relationships with Glucose and Insulin Following Ingestion of Different Classes of Macronutrients

Overview

Journal Nutrients

Date 2022 Jan 21

PMID 35057557

Authors

Christian Gobl

Micaela Morettini

Benedetta Salvatori

Wathik Alsalim

Hana Kahleova

Bo Ahren

Andrea Tura

Affiliations

Soon will be listed here.

Abstract

Background: glucagon secretion and inhibition should be mainly determined by glucose and insulin levels, but the relative relevance of each factor is not clarified, especially following ingestion of different macronutrients. We aimed to investigate the associations between plasma glucagon, glucose, and insulin after ingestion of single macronutrients or mixed-meal.

Methods: thirty-six participants underwent four metabolic tests, based on administration of glucose, protein, fat, or mixed-meal. Glucagon, glucose, insulin, and C-peptide were measured at fasting and for 300 min following food ingestion. We analyzed relationships between time samples of glucagon, glucose, and insulin in each individual, as well as between suprabasal area-under-the-curve of the same variables (ΔAUC, ΔAUC, ΔAUC) over the whole participants' cohort.

Results: in individuals, time samples of glucagon and glucose were related in only 26 cases (18 direct, 8 inverse relationships), whereas relationship with insulin was more frequent (60 and 5, < 0.0001). The frequency of significant relationships was different among tests, especially for direct relationships ( ≤ 0.006). In the whole cohort, ΔAUC was weakly related to ΔAUC ( ≤ 0.02), but not to ΔAUC, though basal insulin secretion emerged as possible covariate.

Conclusions: glucose and insulin are not general and exclusive determinants of glucagon secretion/inhibition after mixed-meal or macronutrients ingestion.

Citing Articles

Glucagon kinetics assessed by mathematical modelling during oral glucose administration in people spanning from normal glucose tolerance to type 2 diabetes.

Andreozzi F, Mancuso E, Rubino M, Salvatori B, Morettini M, Monea G Front Endocrinol (Lausanne). 2024; 15:1376530.

PMID: 38681771 PMC: 11045965. DOI: 10.3389/fendo.2024.1376530.

Robust increase in glucagon secretion after oral protein intake, but not after glucose or lipid intake in Japanese people without diabetes.

Ichikawa R, Takano K, Fujimoto K, Kobayashi M, Kitamura T, Shichiri M J Diabetes Investig. 2023; 14(10):1172-1174.

PMID: 37480216 PMC: 10512907. DOI: 10.1111/jdi.14053.

Chemical Compounds and Ambient Factors Affecting Pancreatic Alpha-Cells Mass and Function: What Evidence?.

Mannino G, Mancuso E, Sbrignadello S, Morettini M, Andreozzi F, Tura A Int J Environ Res Public Health. 2022; 19(24).

PMID: 36554367 PMC: 9778390. DOI: 10.3390/ijerph192416489.

The relationship between insulin and glucagon concentrations in non-diabetic humans.

Laurenti M, Arora P, Dalla Man C, Andrews J, Rizza R, Matveyenko A Physiol Rep. 2022; 10(13):e15380.

PMID: 35822422 PMC: 9277417. DOI: 10.14814/phy2.15380.

References

Ahren B . Glucagon--Early breakthroughs and recent discoveries. Peptides. 2015; 67:74-81. DOI: 10.1016/j.peptides.2015.03.011. View

Pipeleers D, Schuit F, Int Veld P, Maes E, Hooghe-Peters E, Van De Winkel M . Interplay of nutrients and hormones in the regulation of insulin release. Endocrinology. 1985; 117(3):824-33. DOI: 10.1210/endo-117-3-824. View

Zhang Q, Ramracheya R, Lahmann C, Tarasov A, Bengtsson M, Braha O . Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 2013; 18(6):871-82. PMC: 3851686. DOI: 10.1016/j.cmet.2013.10.014. View

Gromada J, Chabosseau P, Rutter G . The α-cell in diabetes mellitus. Nat Rev Endocrinol. 2018; 14(12):694-704. DOI: 10.1038/s41574-018-0097-y. View

Bolli G, Dimitriadis G, Pehling G, Baker B, Haymond M, Cryer P . Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. N Engl J Med. 1984; 310(26):1706-11. DOI: 10.1056/NEJM198406283102605. View

Morettini M, Burattini L, Gobl C, Pacini G, Ahren B, Tura A . Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test. Front Endocrinol (Lausanne). 2021; 12:611147. PMC: 8020816. DOI: 10.3389/fendo.2021.611147. View

Ahren B, Taborsky Jr G . The mechanism of vagal nerve stimulation of glucagon and insulin secretion in the dog. Endocrinology. 1986; 118(4):1551-7. DOI: 10.1210/endo-118-4-1551. View

Gromada J, Franklin I, Wollheim C . Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev. 2007; 28(1):84-116. DOI: 10.1210/er.2006-0007. View

Prip-Buus C, Pegorier J, Duee P, Kohl C, Girard J . Evidence that the sensitivity of carnitine palmitoyltransferase I to inhibition by malonyl-CoA is an important site of regulation of hepatic fatty acid oxidation in the fetal and newborn rabbit. Perinatal development and effects of pancreatic.... Biochem J. 1990; 269(2):409-15. PMC: 1131592. DOI: 10.1042/bj2690409. View

10.

Zhang Q, Chibalina M, Bengtsson M, Groschner L, Ramracheya R, Rorsman N . Na+ current properties in islet α- and β-cells reflect cell-specific Scn3a and Scn9a expression. J Physiol. 2014; 592(21):4677-96. PMC: 4253470. DOI: 10.1113/jphysiol.2014.274209. View

11.

Alsalim W, Tura A, Pacini G, Omar B, Bizzotto R, Mari A . Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes. Diabetes Obes Metab. 2015; 18(1):24-33. DOI: 10.1111/dom.12570. View

12.

Tura A, Muscelli E, Gastaldelli A, Ferrannini E, Mari A . Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. Diabetologia. 2014; 57(6):1199-203. DOI: 10.1007/s00125-014-3219-7. View

13.

Ohlsson L, Alsalim W, Carr R, Tura A, Pacini G, Mari A . Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Diabetes Obes Metab. 2013; 15(6):531-7. DOI: 10.1111/dom.12062. View

14.

Chung W, Erion K, Florez J, Hattersley A, Hivert M, Lee C . Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43(7):1617-1635. PMC: 7305007. DOI: 10.2337/dci20-0022. View

15.

Ahren B . Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013; 9:155-63. PMC: 3639216. DOI: 10.2147/VHRM.S33934. View

16.

Omar B, Sorhede-Winzell M, Ahren B . Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function. Metabolism. 2014; 63(12):1568-76. DOI: 10.1016/j.metabol.2014.09.004. View

17.

Rorsman P, Berggren P, Bokvist K, Ericson H, Mohler H, Ostenson C . Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. Nature. 1989; 341(6239):233-6. DOI: 10.1038/341233a0. View

18.

Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J . Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015; 21(5):512-7. DOI: 10.1038/nm.3828. View

19.

Vergari E, Knudsen J, Ramracheya R, Salehi A, Zhang Q, Adam J . Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. Nat Commun. 2019; 10(1):139. PMC: 6329806. DOI: 10.1038/s41467-018-08193-8. View

20.

Bergman M, Abdul-Ghani M, DeFronzo R, Manco M, Sesti G, Fiorentino T . Review of methods for detecting glycemic disorders. Diabetes Res Clin Pract. 2020; 165:108233. PMC: 7977482. DOI: 10.1016/j.diabres.2020.108233. View